Clinical Trial Update: A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, tolerability and pharmacokinetics of single and repeat doses of CHF6333 in healthy subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Non-cystic Fibrosis Bronchiectasis

Drugs mentioned

• CHF6333

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Non-Cystic Fibrosis Bronchiectasis, Cystic Fibrosis | Phase 1 | Status: COMPLETED